Working... Menu

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01057147
Recruitment Status : Completed
First Posted : January 27, 2010
Last Update Posted : January 11, 2012
Otsuka Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Acucela Inc.

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of 2% rebamipide compared to placebo in clearing of fluorescein staining of the central cornea in subjects with dry eye disease.

Condition or disease Intervention/treatment Phase
Keratoconjunctivitis Sicca Dry Eye Drug: rebamipide 2% ophthalmic suspension Drug: placebo eye drops Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 116 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Prospective, Randomized, Double-masked, Parallel Group, Multi-center Study Assessing the Safety and Efficacy of 2% Rebamipide (OPC-12759) Compared to Placebo in Clearing of Fluorescein Staining of the Central Cornea in Subjects With Keratoconjunctivitis Sicca (Dry Eye)
Study Start Date : February 2010
Actual Primary Completion Date : January 2011
Actual Study Completion Date : February 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: rebamipide 2% ophthalmic suspension Drug: rebamipide 2% ophthalmic suspension
Instill one drop in each eye four times daily for 12 weeks.

Placebo Comparator: placebo eye drops Drug: placebo eye drops
Instill one drop in each eye four times daily for 12 weeks.

Primary Outcome Measures :
  1. Central corneal clearing as measured by fluorescein staining [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Ocular staining [ Time Frame: 12 weeks ]
  2. Dry eye symptoms [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years and older
  • Diagnosis of dry eye as defined by the protocol
  • Central corneal staining

Exclusion Criteria:

  • Ongoing ocular disease that may interfere with study parameters
  • Inability to stop using topical ophthalmic medications throughout the duration of the study
  • Inability to stop the use of contact lenses for the duration of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01057147

Layout table for location information
United States, Arizona
East Valley Ophthalmology
Mesa, Arizona, United States, 85206
Arizona Center for Clinical Trials, LLC
Phoenix, Arizona, United States, 85003
Cornea Consultants of Arizona
Phoenix, Arizona, United States, 85032
United States, California
Macy Eye Center
Los Angeles, California, United States, 90048
United States, Colorado
Corneal Consultants of Colorado
Littleton, Colorado, United States, 80120
Specialty Eye Care
Parker, Colorado, United States, 80134
United States, Florida
Cohen Laser and Vision Center
Boca Raton, Florida, United States, 33431
Florida Eye Microsurgical Institute, Inc.
Boynton Beach, Florida, United States, 33426
Med Eye Associates
Miami, Florida, United States, 33143
United States, Kentucky
George R. John, MD
Louisville, Kentucky, United States, 40205
United States, Maine
Central Maine Eye Care
Lewiston, Maine, United States, 04240
United States, Massachusetts
Ora, Inc.
Andover, Massachusetts, United States, 01810
United States, Missouri
Ophthalmology Associates
St. Louis, Missouri, United States, 63131
United States, Nevada
Nevada Eye Care Professionals
Las Vegas, Nevada, United States, 89119
Avista Eye Center
Las Vegas, Nevada, United States, 89131
United States, New York
New York Ophthalmology, PC
Manhasset, New York, United States, 11030
United States, North Carolina
Mundorf Eye Center
Charlotte, North Carolina, United States, 28204
United States, South Dakota
Black Hills Regional Eye Institute
Rapid City, South Dakota, United States, 57701
United States, Texas
The Cataract & Glaucoma Center
El Paso, Texas, United States, 79902
Sponsors and Collaborators
Acucela Inc.
Otsuka Pharmaceutical Co., Ltd.
Layout table for investigator information
Study Director: Ryo Kubota, MD, PhD Acucela Inc.

Layout table for additonal information
Responsible Party: Acucela Inc. Identifier: NCT01057147     History of Changes
Other Study ID Numbers: ACU-RED-204
First Posted: January 27, 2010    Key Record Dates
Last Update Posted: January 11, 2012
Last Verified: January 2012

Additional relevant MeSH terms:
Layout table for MeSH terms
Dry Eye Syndromes
Eye Diseases
Ophthalmic Solutions
Keratoconjunctivitis Sicca
Conjunctival Diseases
Corneal Diseases
Lacrimal Apparatus Diseases
Pharmaceutical Solutions
Anti-Ulcer Agents
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Enzyme Inhibitors